Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels.

Eicher, Florian; Mansouri Taleghani, Behrouz; Schild, Christof; Bacher, Vera; Pabst, Thomas (2020). Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels. Hematological oncology, 38(4), pp. 523-530. Wiley 10.1002/hon.2774

[img] Text
reduced surv.pdf - Accepted Version
Restricted to registered users only until 1 July 2021.
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is applied for consolidation in myeloma and relapsing lymphoma patients. Vitamin D (VitD) exerts effects during hematopoietic stem cell proliferation, differentiation and interactions with the immune system. VitD deficiency is frequent in patients with hematological malignancies, but its prognostic relevance after ASCT remains unclear. We investigated the effect of VitD serum levels in patients with lymphomas and myeloma at ASCT on progression-free (PFS) and overall survival (OS). The cohort (n = 183) was divided in two groups: 81 (44%) had VitD levels >52 nmol/L and 102 (56%) ≤52 nmol/L at ASCT. VitD levels >52 nmol/L were associated with better PFS (P = 0.0194) and OS (P = 0.011). Similarly, when evaluating myeloma patients alone, patients with lower VitD levels (≤52 nmol/L) had inferior PFS (P = 0.0412) and OS (P = 0.049). Finally, the multivariate analysis was consistent that varying VitD levels were significantly associated with OS (P = 0.0167), also when stratifying patients in groups with VitD levels > vs ≤52 nmol/L (P = 0.0421). Our data suggest that reduced serum VitD levels in myeloma and lymphoma patients undergoing HDCT/ASCT are associated with inferior outcome. Optimizing VitD levels before ASCT may be warranted. This article is protected by copyright. All rights reserved.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Mansouri Taleghani, Behrouz; Schild, Christof; Bacher, Vera Ulrike and Pabst Müller, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1099-1069

Publisher:

Wiley

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

07 Jul 2020 09:24

Last Modified:

24 Oct 2020 01:33

Publisher DOI:

10.1002/hon.2774

PubMed ID:

32594534

Uncontrolled Keywords:

Vitamin D autologous stem cell transplantation (ASCT) deficiency lymphoma multiple myeloma prognosis

BORIS DOI:

10.7892/boris.145059

URI:

https://boris.unibe.ch/id/eprint/145059

Actions (login required)

Edit item Edit item
Provide Feedback